Dentsply Sirona Inc (XRAY)

Sep 25, 2026

This article analyzes the Q2 performance of several dental equipment and technology stocks, highlighting Dentsply Sirona (XRAY), Envista (NVST), Align Technology (ALGN), and Henry Schein (HSIC). It details their revenue growth, performance against analyst estimates, and stock price reactions, noting that the sector experienced strong Q2 revenues but subsequent stock price declines. The piece also touches on broader market shifts, including concerns over AI and geopolitics impacting investor focus.

Sep 23, 2026

Bank of America Corp DE has acquired 2.92 million shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY), valued at approximately $31 million, marking a new 1.47% stake in the company. Institutional investors collectively hold 95.7% of DENTSPLY SIRONA's stock, with several firms increasing or initiating positions. Despite analysts maintaining a "Hold" rating with a target price of $13.31, the medical instruments supplier recently beat quarterly earnings estimates but experienced a 4.1% year-over-year revenue decline.

Sep 20, 2026

Squarepoint Ops LLC significantly reduced its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by selling 431,734 shares, retaining 55,600 shares valued at approximately $590,000. Despite beating EPS estimates, the medical instruments supplier's revenue declined year-over-year. Analysts currently hold a consensus "Hold" rating for XRAY with an average target price of $13.31.

Sep 18, 2026

DENTSPLY SIRONA (NASDAQ:XRAY) stock recently hit a new 52-week low of $9.36. Despite exceeding quarterly EPS and revenue estimates, the company experienced a 4.1% year-over-year revenue decline and a negative net margin. Analyst sentiment is mixed, with a consensus "Hold" rating and a target price of $13.31, while institutional investors hold a significant majority of the stock.

Sep 17, 2026

Amundi significantly reduced its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 85.6% in the second quarter, selling over 240,000 shares. Despite this, institutional investors collectively own approximately 95.7% of the company's stock, with several other funds either initiating or increasing their positions. Analysts currently have a consensus "Hold" rating on XRAY with an average price target of $13.54, even though the company recently beat EPS and revenue estimates while experiencing a year-over-year revenue decline.